474659-26-2 Usage
Uses
Used in Pharmaceutical Industry:
3-Quinolinecarboxylic acid,7-methoxy-(9CI) is used as an antimicrobial agent for its potential to combat various types of bacteria, making it a valuable component in the development of new antibiotics to address the growing issue of antibiotic resistance.
3-Quinolinecarboxylic acid,7-methoxy-(9CI) is also used as an antifungal agent for its potential to treat fungal infections, offering a new approach to managing and treating various fungal diseases.
Used in Anti-inflammatory Applications:
3-Quinolinecarboxylic acid,7-methoxy-(9CI) is used as an anti-inflammatory agent for its potential to reduce inflammation, which could be beneficial in the treatment of various inflammatory conditions.
Used in Antiproliferative Applications:
3-Quinolinecarboxylic acid,7-methoxy-(9CI) is used as an antiproliferative agent for its potential to inhibit the proliferation of certain types of cells, which may have implications in the treatment of cancer and other hyperproliferative disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 474659-26-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,4,6,5 and 9 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 474659-26:
(8*4)+(7*7)+(6*4)+(5*6)+(4*5)+(3*9)+(2*2)+(1*6)=192
192 % 10 = 2
So 474659-26-2 is a valid CAS Registry Number.
InChI:InChI=1/C11H9NO3/c1-15-9-3-2-7-4-8(11(13)14)6-12-10(7)5-9/h2-6H,1H3,(H,13,14)
474659-26-2Relevant articles and documents
OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS
-
Paragraph 0048, (2018/07/31)
Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the structure (I) in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar dise
Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1- {[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl) -1,2,3,4-tetrahydro-3-is
Cai, Tingwei Bill,Zou, Zhou,Thomas, James B.,Brieaddy, Larry,Navarro, Hernán A.,Carroll, F. Ivy
, p. 1849 - 1860 (2008/09/21)
In previous structure-activity relationship (SAR) studies, we identified (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1- piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3- isoquinolinecarboxamide (JDTic, 1) as the first poten
SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
-
Page/Page column 38, (2008/06/13)
The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes
